Skip to main content
Equibles
CRVS logo

CRVS · Corvus Pharmaceuticals, Inc. · Earnings Call Transcripts & Audio

Track CRVS — free

Use CRVS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CRVS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$12.91 -0.03 (-0.23%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$1.09B
Shares
84.12M

Corvus Pharmaceuticals, Inc. Earnings Call Transcripts

Quarterly earnings calls for Corvus Pharmaceuticals, Inc. (CRVS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Conference
Investor event
2026-09-10
Corvus Pharmaceuticals, Inc. (CRVS) September 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-06
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Confident tone Pipeline Expansion (HS and Asthma) ANGEL Pharmaceuticals Partnership (China) Financial Position / Cash Runway
Diluted EPS
$-0.19
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Corvus Pharmaceuticals, Inc. (CRVS) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-03
Corvus Pharmaceuticals, Inc. (CRVS) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2026 Earnings Call Transcript
Confident tone ITK mechanism and Treg induction Phase 2 atopic dermatitis design and timing Cash runway and financing need
Diluted EPS
$-0.15
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-12
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Confident tone Soquelitinib clinical efficacy in atopic dermatitis Phase II atopic dermatitis trial Pipeline expansion to other inflammatory diseases
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript
Confident tone Soquelitinib atopic dermatitis program Phase II atopic dermatitis trial design Peripheral T cell lymphoma (PTCL) Phase III
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Confident tone Soquelitinib in atopic dermatitis Phase I Cohort 3 efficacy and safety China partnership with Angel Pharmaceuticals
Diluted EPS
$-0.10
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-08
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
Confident tone Soquelitinib atopic dermatitis Phase 1 efficacy Phase 2 atopic dermatitis trial planning Dose selection and pharmacokinetics
Diluted EPS
$-0.13
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-25
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
Confident tone Socalitinib in atopic dermatitis Socalitinib in T-cell lymphoma (PTCL) ALPS (NIH trial)
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
Positive tone Soquelitinib in atopic dermatitis (Phase I) December data readout / upcoming catalysts ITK mechanism and Treg/Th17 biology
Diluted EPS
$-0.60
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call
Diluted EPS
$-0.07
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript
Confident tone Soquelitinib Phase III in PTCL Soquelitinib in Atopic Dermatitis Ciforadenant in Renal Cell Cancer
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-03-19
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
Confident tone Soquelitinib registrational Phase 3 trial in relapsed PTCL Phase 1 trial of soquelitinib in atopic dermatitis Business development and partnering
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2023 Earnings Call Transcript
Diluted EPS
$-0.12
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-08
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2023 Earnings Call Transcript
Diluted EPS
$-0.14
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2023 Earnings Call Transcript
Diluted EPS
$-0.17
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-03-28
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2022 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2022 Earnings Call Transcript
Diluted EPS
$-0.32
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2022 Earnings Call Transcript
Diluted EPS
$-0.18
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-05
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2022 Earnings Call
Diluted EPS
$-0.18
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-10
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2021 Earnings Call Transcript
Diluted EPS
$-0.20
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q2
2021-07-15
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2021 Earnings Call
Diluted EPS
$-0.28
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-07-30
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-04-30
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2020 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-05
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2019 Earnings Call
Diluted EPS
$0.92
Audio Transcript Slides 8-K10-K
Showing 1–26 of 26 earnings calls
Key facts CIK 1626971 CUSIP 221015100 13F (30d) 61 filings 61 filers Visit website Investor relations